Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shionogi & Co ( (JP:4507) ) has issued an announcement.
Shionogi & Co., Ltd. announced a strategic move to acquire the pharmaceutical business of Japan Tobacco Inc. and make Akros Pharma Inc. a sub-subsidiary, enhancing its capabilities in small molecule drug discovery. This transaction aligns with Shionogi’s vision of creating a new healthcare platform and aims to accelerate the development of innovative drugs, strengthen its global market position, and contribute to global health by delivering advanced pharmaceuticals.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, focusing on research and development, manufacturing, and sales of prescription and over-the-counter drugs, as well as diagnostic agents. The company is transitioning into a Healthcare as a Service (HaaS) provider, aiming to address global healthcare challenges through innovative solutions. Shionogi has a strong foundation in small molecule drug discovery and is known for developing drugs for infectious diseases and quality of life (QOL) diseases.
Average Trading Volume: 2,482,964
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen2161B
For detailed information about 4507 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue